AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Veliparib'
:
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Publication Year: 2019
DOI: https://doi.org/10.1056/nejmoa1909707
Abstract:
Add to Library
Authors:
Robert L. Coleman
Gini F. Fleming
Mark F. Brady
Elizabeth M. Swisher
Karina Dahl Steffensen
Michael Friedlander
Aikou Okamoto
Kathleen N. Moore
Noa Ben-Baruch
Theresa L. Werner
Noelle Cloven
Ana Oaknin
Paul DiSilvestro
Mark A. Morgan
Joo‐Hyun Nam
Charles A. Leath
Shibani Nicum
Andrea R. Hagemann
Ramey D. Littell
David Cella
Sally Baron‐Hay
Jesús García-Donás
Mika Mizuno
Katherine M. Bell‐McGuinn
Danielle Sullivan
Bruce Allen Bach
Sudipta Bhattacharya
Christine K. Ratajczak
Peter Ansell
Minh H. Dinh
Carol Aghajanian
Michael A. Bookman
Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer
Publication Year: 2016
DOI: https://doi.org/10.1056/nejmoa1513749
Abstract:
Add to Library
Authors:
Hope S. Rugo
Olufunmilayo I. Olopade
Angela DeMichele
Christina Yau
Laura van ‘t Veer
Meredith Buxton
Michael Hogarth
Nola M. Hylton
Melissa Paoloni
Jane Perlmutter
W. Fraser Symmans
Douglas Yee
A. Jo Chien
Anne M. Wallace
Henry G. Kaplan
Judy C. Boughey
Tufia C. Haddad
Kathy S. Albain
Minetta C. Liu
Claudine Isaacs
Qamar J. Khan
Julie E. Lang
Rebecca K. Viscusi
Lajos Pusztai
Stacy L. Moulder
Jane Yuet Ching Hui
Kathleen Kemmer
Anthony Elias
Kirsten K. Edmiston
David Euhus
Barbara Haley
Rita Nanda
Donald W. Northfelt
Debasish Tripathy
William C. Wood
Cheryl A. Ewing
Richard B. Schwab
Julia Lyandres
Sarah Davis
Gillian L. Hirst
Ashish Sanil
Donald A. Berry
Laura J. Esserman
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Publication Year: 2018
DOI: https://doi.org/10.1016/s1470-2045(18)30111-6
Abstract:
Add to Library
Authors:
Sibylle Loibl
Joyce O’Shaughnessy
Michael Untch
William M. Sikov
Hope S. Rugo
Mark D. McKee
Jens Huober
Mehra Golshan
Gϋnter von Minckwitz
David Maag
Danielle Sullivan
Norman Wolmark
Kristi McIntyre
José Ponce
Otto Metzger
Priya Rastogi
W. Fraser Symmans
Xuan Liu
Charles E. Geyer
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
Publication Year: 2018
DOI: https://doi.org/10.1200/jco.2018.77.7672
Abstract:
Add to Library
Authors:
M. Catherine Pietanza
Saiama N. Waqar
Lee M. Krug
Afshin Dowlati
Christine L. Hann
Alberto Chiappori
Taofeek K. Owonikoko
Kaitlin M. Woo
Robert J. Cardnell
Junya Fujimoto
Lihong Long
Lixia Diao
Jing Wang
Yevgeniva Bensman
Brenda Hurtado
Patricia M. de Groot
Erik P. Sulman
Ignacio I. Wistuba
Alice Chen
Martin Fleisher
John V. Heymach
Mark G. Kris
Charles M. Rudin
Lauren A. Byers
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas
Publication Year: 2012
DOI: https://doi.org/10.1158/1078-0432.ccr-11-2821
Abstract:
Add to Library
Authors:
Shivaani Kummar
Jiuping Ji
Robert J. Morgan
Heinz-Josef Lenz
Shannon L. Puhalla
Chandra P. Belani
David R. Gandara
Deborah Allen
Brian F. Kiesel
Jan H. Beumer
Edward M. Newman
Larry Rubinstein
Alice Chen
Yiping Zhang
Lihua Wang
Robert J. Kinders
Ralph E. Parchment
Joseph E. Tomaszewski
James H. Doroshow
A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.
Publication Year: 2010
DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.1019
Abstract:
Add to Library
Authors:
SJ Isakoff
Beth Overmoyer
Nadine Tung
R. S. Gelman
Vincent L. Giranda
Klumpp Bernhard
Karleen Habin
Leif W. Ellisen
Eric P. Winer
Paul E. Goss
Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
Publication Year: 2015
DOI: https://doi.org/10.1093/jnci/djv369
Abstract:
Add to Library
Authors:
Shiv K. Gupta
Sani H. Kizilbash
Brett L. Carlson
Ann C. Mladek
Felix Boakye‐Agyeman
Katrina K. Bakken
Jenny L. Pokorny
Mark A. Schroeder
Paul A. Decker
Ling Cen
Jeanette E. Eckel‐Passow
Gobinda Sarkar
Karla V. Ballman
Joel M. Reid
Robert B. Jenkins
Roeland Verhaak
Erik P. Sulman
Gaspar J. Kitange
Jann N. Sarkaria
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
Publication Year: 2020
DOI: https://doi.org/10.1016/s1470-2045(20)30447-2
Abstract:
Add to Library
Authors:
Véronique Dièras
Hyo S. Han
Bella Kaufman
Hans Wildiers
Michael Friedlander
Jean-Pierre Ayoub
Shannon L. Puhalla
Igor Bondarenko
Mario Campone
Erik Jakobsen
Mathilde Jalving
Cristina Oprean
Markéta Palácová
Yeon Hee Park
Yaroslav Shparyk
Eduardo Yáñez
Nikhil Khandelwal
Madan G. Kundu
Matthew W. Dudley
Christine K. Ratajczak
David Maag
Banu K. Arun
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline <i>BRCA/PALB2</i> Mutation
Publication Year: 2020
DOI: https://doi.org/10.1200/jco.19.02931
Abstract:
Add to Library
Authors:
Eileen M. O’Reilly
Jonathan W. Lee
Mark M. Zalupski
Marinela Capanu
Jennifer Park
Talia Golan
Esther Tahover
Maeve A. Lowery
Joanne F. Chou
Vaibhav Sahai
Robin Brenner
Hedy L. Kindler
Kenneth H. Yu
Alice Zervoudakis
Shreya Vemuri
Zsofia K. Stadler
Richard Kinh Gian
Neesha C. Dhani
Alice Chen
David P. Kelsen
Profile of veliparib and its potential in the treatment of solid tumors
Publication Year: 2015
DOI: https://doi.org/10.2147/ott.s69935
Abstract:
Add to Library
Authors:
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
Publication Year: 2018
DOI: https://doi.org/10.1200/jco.18.00264
Abstract:
Add to Library
Authors:
Taofeek K. Owonikoko
Suzanne E. Dahlberg
Gabriel Sica
Lynne I. Wagner
James L. Wade
Gordan Srkalović
Bradley W. Lash
Joseph W. Leach
Ticiana B. Leal
Charu Aggarwal
Suresh S. Ramalingam
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
Publication Year: 2019
DOI: https://doi.org/10.1016/j.ebiom.2018.12.060
Abstract:
Add to Library
Authors:
Richard Tuli
Stephen L. Shiao
Nicholas N. Nissen
Mourad Tighiouart
Sungjin Kim
Arsen Osipov
Miranda Bryant
Lindsey Ristow
Veronica Placencio-Hickok
David Hoffman
Sepehr Rokhsar
Kevin S. Scher
Samuel J. Klempner
Paul Noe
Madison Davis
Ashley Wachsman
Simon S. Lo
Laith H. Jamil
Howard M. Sandler
Steven Piantadosi
Andrew Hendifar
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <i>BRCA</i>-Mutant Ovarian Cancer
Publication Year: 2015
DOI: https://doi.org/10.1158/1078-0432.ccr-14-2565
Abstract:
Add to Library
Authors:
Shivaani Kummar
Amit M. Oza
Gini F. Fleming
Daniel M. Sullivan
David R. Gandara
Michael Naughton
Miguel A. Villalona‐Calero
Robert J. Morgan
Péter Szabò
Ahrim Youn
Alice Chen
Jiuping Ji
Deborah Allen
Chih-Jian Lih
Michele G. Mehaffey
William D. Walsh
Paul M. McGregor
Seth M. Steinberg
P. Mickey Williams
Robert J. Kinders
Barbara A. Conley
Richard Simon
James H. Doroshow
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
Publication Year: 2022
DOI: https://doi.org/10.1016/j.annonc.2022.01.009
Abstract:
Add to Library
Authors:
Charles E. Geyer
William M. Sikov
Jens Huober
Hope S. Rugo
Norman Wolmark
J. O’Shaughnessy
David Maag
Michael Untch
Mehra Golshan
José Ponce
Otto Metzger
Martin Dunbar
W. Fraser Symmans
Priya Rastogi
Joohyuk Sohn
Robyn R. Young
Gail S. Wright
C. Harkness
Kristi McIntyre
Denise A. Yardley
Sibylle Loibl
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
Publication Year: 2017
DOI: https://doi.org/10.1016/j.ejca.2017.11.004
Abstract:
Add to Library
Authors:
Maeve A. Lowery
David P. Kelsen
Marinela Capanu
Sloane C. Smith
Jonathan W. Lee
Zsofia K. Stadler
Malcolm J. Moore
Hedy L. Kindler
Talia Golan
Amiel Segal
Hannah Maynard
Ellen Hollywood
Mary Ellen Moynahan
Erin Salo‐Mullen
Richard Kinh Gian
Alice Chen
Kenneth H. Yu
Laura H. Tang
Eileen M. O’Reilly
Found 4642 results in 0.055 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"